Global News

Emma Walmsley to succeed Andrew Witty as CEO of GlaxoSmithKline

Wednesday, September 21, 2016

GSK has announced that Emma Walmsley, currently chief executive officer (CEO) of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO when he retires on March 31, 2017. Walmsley will join the GSK board of directors January 2017.

[Read More]

Bayer, Evotec partner on kidney diseases treatments

Wednesday, September 21, 2016

Bayer and Evotec have entered into a five-year, multi-target research partnership to develop multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during preclinical development of potential clinical candidates.

[Read More]

Allergan to acquire Tobira Therapeutics for $1.7B

Wednesday, September 21, 2016

Allergan, a global pharmaceutical company, and Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, have entered into a definitive agreement under which Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.

[Read More]

Zafgen initiates phase I trial of ZGN-1061

Wednesday, September 21, 2016

Zafgen, a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, has announced that the company has recently initiated dosing in the multiple ascending dose (MAD) cohorts of its ongoing phase I clinical trial of ZGN-1061. The initiation of the MAD portion was triggered following a review of the initial safety and tolerability data from the first two cohorts of the single ascending dose (SAD) portion of the clinical trial. ZGN-1061 is a second-generation, differentiated MetAP2 inhibitor in development for severe and complicated obesity indications.  

[Read More]

Pediatric Cancer Foundation to honor Congressmen McCaul & Van Hollen

Wednesday, September 21, 2016

Congressman Michael Mccaul and Congressman Chris Van Hollen to be honored at the 3rd Annual Golden Toast. The Golden Toast represents bipartisan politics at its finest. It is an evening when members of Congress from both sides of the aisle demonstrate a commitment to some of the most vulnerable members of society—children who are fighting cancer. In an election season marked by divisiveness, the Golden Toast is a visible reminder that our elected officials can put aside disagreements to accomplish meaningful change and advance life-saving research. 

[Read More]

Report: Osteoarthritis space set to approach $10.5B by 2024

Tuesday, September 20, 2016

The osteoarthritis market across the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K., and Japan is forecast to more than treble from $3.25 billion in 2014 to $10.49 billion by 2024, representing a compound annual growth rate of 17.8%, according to research and consulting firm GlobalData.

[Read More]